Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa.
1 alpha-Monofluoromethyldopa (MFMD, RMI 71963), a potent and selective enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase produces a substantial and long-lasting decrease in the catecholamine content of mouse brain, heart and kidney. 2 Single doses of MFMD reduce the 5-hydroxytryptamine concentration of mouse brain without altering the tryptophan concentration. 3 In animals treated with MFMD, peripheral but not brain noradrenaline is restored within 1 h to control levels by an intraperitoneal injection of dopamine.
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001923:Brain Chemistry / Q000187:drug effects; D002395:Catecholamines / Q000096:biosynthesis*; D004298:Dopamine / Q000096:biosynthesis / Q000494:pharmacology; D008297:Male; D008750:Methyldopa / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D012701:Serotonin / Q000378:metabolism; D013997:Time Factors; D014364:Tryptophan / Q000096:biosynthesis
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002395:Catecholamines; D012701:Serotonin; D008750:Methyldopa; C019494:alpha-monofluoromethyldopa; D014364:Tryptophan; D004298:Dopamine